Next Generation of Genetic Engineered AAV Helper Plasmids

Discover how genetic engineering of AAV helper genes can improve your AAV process manufacturing.

Register Free: https://www.biopharminternational.com/bp_w/genetic-engineered-aav

Event Overview:

Harnessing rAAVs as viral vectors for therapeutic transgene delivery still requires improvements in yields and specificity to lower vector doses, and therefore manufacturing cost, as well as to improve patient safety. To this end, research is focused on developing novel technologies to ensure manufacturing of high yielding rAAV particles using transient transfection.

Join this webinar to hear from Eric Mauro, plasmid engineering scientist, Polyplus, and Goutham Kumar Ganjam, head of manufacturing, DiNAMIQS, as they discuss Polyplus’ state-of-the art approach to design new helper plasmids (phelpers) with the aim of improving both the infectiosity (TU/mL) and the quality (full/empty ratio) of the viral particle in suspension systems. Eric and Goutham will also highlight how DiNAMIQS evaluated these novel helper plasmids in their manufacturing platform and what was learned about the potential to improve both productivity and quality of rAAV produced.

Key Learning Objectives:

• Strategies to improve AAV helper plasmid engineering.
• Role of engineering of helper plasmid to improve AAV yield and quality.
  

Featured Speakers:

Eric Mauro
Plasmid Engineering Scientist

Eric Mauro received his PhD in virology, working on retroviruses in Bordeaux (France) in 2018. Eric moved on to carry out postdoctoral training and worked on the development of therapeutic drugs against retroviruses. He then joined the plasmid engineering site of Polyplus, a Sartorius Company, as a plasmid engineering scientist in 2020. In his current role, Eric develops strategies to improve rAAV production for gene therapy.

Goutham Kumar Ganjam
Head of Manufacturing
DiNAMIQS

Goutham Kumar Ganjam is head of AAV manufacturing at DiNAMIQs, a Siegfreid company, based in Zurich Switzerland, and is responsible for delivering R&D grade AAV to accelerate AAV-based gene therapies from proof-of-concept studies to TOX studies. He is involved in early process development, from gene cassette optimization, to suspension-based AAV manufacturing up to 50L scale. Goutham earned his PhD in Biochemistry from Georg-August University of Göttingen. The author of more than 20 scientific publications, Goutham developed AAV-based neurodegenerative and metabolic disease models supported by Roche, ParkinsonFonds, Rönten-Behring and Deutcsche Forschungsgemeinshaft.

Register Free: https://www.biopharminternational.com/bp_w/genetic-engineered-aav